Search

Displaying results 2871 - 2880 of 10000 in total
  1. Drug

    Enmetazobactam

    go.drugbank.com/drugs/DB18716
    ApprovedInvestigational

    [A263276] The combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections. … [A263266] Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious

  2. Drug

    Copper histidinate

    go.drugbank.com/drugs/DB32041
    Approved

    in severe systemic copper deficiency. … [A275383,T903] In patients with the disease, defects in this transporter lead to the entrapment of copper in the intestinal lining and a subsequent inability to absorb it into the bloodstream, resulting

  3. Drug

    PRO 2000

    go.drugbank.com/drugs/DB05385
    Investigational

    PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Lumiracoxib

    go.drugbank.com/drugs/DB01283
    ApprovedWithdrawn

    New Zealand and Canada have also followed suit in recalling the drug. … On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver

  5. Drug

    Pasireotide

    go.drugbank.com/drugs/DB06663
    ApprovedInvestigational

    It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.

  6. Drug

    Nilutamide

    go.drugbank.com/drugs/DB00665
    ApprovedInvestigational

    Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer.

  7. Drug

    Susoctocog alfa

    go.drugbank.com/drugs/DB11606
    ApprovedInvestigational

    AHA is a rare bleeding disorder that results in a prolonged clotting time as measured by the activated partial thromboplastin time (aPTT) assay, a conventional in vitro test for biological activity of … Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for intravenous injection.

    Synonyms: RECOMBINANT DNA DERIVED B-DOMAIN DELETED PORCINE BLOODCOAGULATION FACTOR VIII ANALOGUE, PRODUCED IN BHK21 CELLS: DES-(753-1418)-BLOOD-COAGULATION FACTOR VIII (PROCOAGULANT COMPONENT) SUS SCROFA, GLYCOSYLATED
  8. Drug

    Odronextamab

    go.drugbank.com/drugs/DB16684
    ApprovedInvestigational

    The partial clinical hold was later lifted in May 2021. … [A254192] Odronextamab received its first approval in the European Union on August 26, 2024, for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma

  9. Drug

    Thrombin alfa

    go.drugbank.com/drugs/DB11572
    Approved

    Thrombin Alfa is identical in amino acid sequence and structurally similar to naturally occurring human thrombin. … The cell culture process used in the manufacture of Thrombin Alfa employs no additives of human or animal origin.

  10. Drug

    Ammonia N-13

    go.drugbank.com/drugs/DB09326
    Approved

    Ammonia N 13 Injection, USP is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. … Ammonia N 13 Injection, USP is used for imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease

    Synonyms: Ammonia N 13, Ammonia N-13Products: Ammonia N 13 N 13, Ammonia N 13